title: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
abstract: OBJECTIVE
  We demonstrated that vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates potent, specific, and long-lasting antitumor immunity in multiple murine models and patients with metastatic melanoma. To test whether this vaccination strategy enhances antitumor immunity in patients with metastatic non-small-cell lung cancer (NSCLC), we conducted a phase I clinical trial.
  
  
  METHODS
  Resected metastases were processed to single-cell suspension, infected with a replication-defective adenoviral vector encoding GM-CSF, irradiated, and cryopreserved. Individual vaccines consisted of 1 x 10(6), 4 x 10(6), or 1 x 10(7) cells, depending on overall yield, and were administered intradermally and subcutaneously at weekly and biweekly intervals.
  
  
  RESULTS
  Vaccines were successfully manufactured for 34 (97%) of 35 patients. The average GM-CSF secretion was 513 ng/10(6) cells/24 h. Toxicities were restricted to grade 1 to 2 local skin reactions. Nine patients were withdrawn early because of rapid disease progression. Vaccination elicited dendritic cell, macrophage, granulocyte, and lymphocyte infiltrates in 18 of 25 assessable patients. Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, autologous, nontransfected tumor cells in 18 of 22 patients. Metastatic lesions resected after vaccination showed T lymphocyte and plasma cell infiltrates with tumor necrosis in three of six patients. Two patients surgically rendered as having no evidence of disease at enrollment remain free of disease at 43 and 42 months. Five patients showed stable disease durations of 33, 19, 12, 10, and 3 months. One mixed response was observed.
  
  
  CONCLUSIONS
  Vaccination with irradiated autologous NSCLC cells engineered to secrete GM-CSF enhances antitumor immunity in some patients with metastatic NSCLC.
authors.affiliation: Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Salgia
authors.forename: Thomas
authors.initials: T
authors.lastname: Lynch
authors.forename: Arthur
authors.initials: A
authors.lastname: Skarin
authors.forename: Joan
authors.initials: J
authors.lastname: Lucca
authors.forename: Cathleen
authors.initials: C
authors.lastname: Lynch
authors.forename: Ken
authors.initials: K
authors.lastname: Jung
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Michael
authors.initials: M
authors.lastname: Jaklitsch
authors.forename: Steve
authors.initials: S
authors.lastname: Mentzer
authors.forename: Scott
authors.initials: S
authors.lastname: Swanson
authors.forename: Jean
authors.initials: J
authors.lastname: Lukanich
authors.forename: Raphael
authors.initials: R
authors.lastname: Bueno
authors.forename: John
authors.initials: J
authors.lastname: Wain
authors.forename: Douglas
authors.initials: D
authors.lastname: Mathisen
authors.forename: Cameron
authors.initials: C
authors.lastname: Wright
authors.forename: Panos
authors.initials: P
authors.lastname: Fidias
authors.forename: Dean
authors.initials: D
authors.lastname: Donahue
authors.forename: Shirley
authors.initials: S
authors.lastname: Clift
authors.forename: Steve
authors.initials: S
authors.lastname: Hardy
authors.forename: Donna
authors.initials: D
authors.lastname: Neuberg
authors.forename: Richard
authors.initials: R
authors.lastname: Mulligan
authors.forename: Iain
authors.initials: I
authors.lastname: Webb
authors.forename: David
authors.initials: D
authors.lastname: Sugarbaker
authors.forename: Martin
authors.initials: M
authors.lastname: Mihm
authors.forename: Glenn
authors.initials: G
authors.lastname: Dranoff
mesh_terms: D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000473:pathology / Q000556:secondary; D003131:Combined Modality Therapy; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology / Q000556:secondary; D008297:Male; D008875:Middle Aged
chemical_list: D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor